Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo …
TP Lodise Jr, B Lomaestro, KA Rodvold… - Antimicrobial agents …, 2004 - Am Soc Microbiol
The primary objectives of this analysis were to determine which pharmacokinetic model
most accurately describes the elimination pathways for piperacillin in the presence of …
most accurately describes the elimination pathways for piperacillin in the presence of …
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs
JW Mouton, MN Dudley, O Cars, H Derendorf… - International journal of …, 2002 - Elsevier
Over the last decades, the interest in the relationships between the pharmacokinetics (PK)
and pharmacodynamics (PD) of antimicrobial agents has increased and, therefore, the use …
and pharmacodynamics (PD) of antimicrobial agents has increased and, therefore, the use …
Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella …
PJ Gavin, MT Suseno, RB Thomson Jr… - Antimicrobial agents …, 2006 - Am Soc Microbiol
We assessed infections caused by extended-spectrum-β-lactamase-producing Escherichia
coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility …
coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility …
Clinical pharmacokinetics and pharmacodynamics of tigecycline
A Barbour, S Schmidt, B Ma, L Schiefelbein… - Clinical …, 2009 - Springer
Rapid emergence of resistance against antibacterial s emphasizes the need for the
development of novel and/or more potent antibacterials. Tigecycline is the first …
development of novel and/or more potent antibacterials. Tigecycline is the first …
Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002
JL Kuti, CH Nightingale, DP Nicolau - Antimicrobial agents and …, 2004 - Am Soc Microbiol
The OPTAMA Program is intended to examine typical antimicrobial regimens used in the
treatment of common nosocomial pathogens and the likelihood of these regimens attaining …
treatment of common nosocomial pathogens and the likelihood of these regimens attaining …
Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis
SC Mueller, J Majcher-Peszynska… - Antimicrobial agents …, 2002 - Am Soc Microbiol
The pharmacokinetics of piperacillin-tazobactam were investigated in eight anuric intensive
care patients treated by continuous venovenous hemodialysis (CVVHD). The elimination …
care patients treated by continuous venovenous hemodialysis (CVVHD). The elimination …
Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients
EK Chung, SC Cheatham, MR Fleming… - The Journal of …, 2015 - Wiley Online Library
The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …
Setting antimicrobial susceptibility testing breakpoints: a primer for pediatric infectious diseases specialists on the Clinical and Laboratory Standards Institute …
VM Pierce, AJ Mathers - Journal of the Pediatric Infectious …, 2022 - academic.oup.com
Breakpoints are the values used by clinical microbiology laboratories to interpret the results
of antimicrobial susceptibility testing (AST) and classify isolates as susceptible or resistant …
of antimicrobial susceptibility testing (AST) and classify isolates as susceptible or resistant …
Deconstructing the 2023 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Pseudomonas aeruginosa
PD Tamma, PNA Harris, AJ Mathers… - Clinical Infectious …, 2023 - academic.oup.com
TO THE EDITOR—In January 2023, the Clinical and Laboratory Standards Institute (CLSI)
revised the piperacillintazobactam (PTZ) interpretive criteria against Pseudomonas …
revised the piperacillintazobactam (PTZ) interpretive criteria against Pseudomonas …
Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic …
KM Shea, SC Cheatham, DW Smith… - Annals of …, 2009 - journals.sagepub.com
Background: Prolonging the infusion of a β-lactam antibiotic enhances the time in which
unbound drug concentrations remain above the minimum inhibitory concentration (fT> MIC) …
unbound drug concentrations remain above the minimum inhibitory concentration (fT> MIC) …